 |
|
New drug targets, protein therapeutics and diagnostics for human diseases |
As a global leader in the area of bioinformatics, Compugen has the technology and expertise for rapid and accurate data mining. Using its proprietary gene identification platforms and in-house expertise, Compugen has identified tens of thousands of new human transcripts, including new genes and splice variants of known and novel genes. More on novel splice variants |
|
The novel transcripts were discovered utilizing Compugen’s LEADS platform, a unique assembly process that can identify the existence of novel genes and splice variants using information from various public and non-public sources. Predicted new genes and splice variants were confirmed using additional proprietary gene analysis software available exclusively in-house, as well as by a battery of Ph.D. level scientists with expertise in bioinformatics, pharmacology, genetics and molecular biology. |
|
These tens of thousands of new human transcripts have been divided into 44 functional groups according to their biological activity, including Cancer related genes, Immunology related genes, Neurology related genes, Apoptosis related genes, Kinases, Growth factors, Receptors, Proteases, Hormones, Transporters, Inhibitors, etc. View all groups |
Compugen’s Novel Genomics Laboratory is actively performing "wet" biological research on dozens of selected transcripts from several of the 44 functional groups. So far, this research has revealed potential leads for drug discovery as well as diagnostics for many human diseases. |
Compugen has filed dozens of patent applications on individual genes that have been shown in our laboratories to hold potential as new drug targets, protein therapeutics and diagnostics for human diseases, including Central nervous system disorders, such as Alzheimer’s disease, Parkinson’s disease, psychiatric disorders, stroke and spinal cord injury, cancer, immune diseases, inflammation, allergy, asthma, autoimmune diseases, including diabetes, rheumatoid arthritis, lupus and multiple sclerosis, graft vs. host disease and transplantation, cardiovascular disease, liver disease, hormonal and metabolic disorders, osteoporosis, AIDS and other infectious diseases. |
Compugen is seeking R&D collaborations with biotech and pharma companies to commercialize products based on its proprietary genes. |
|
|
